최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.30 no.1, 2020년, pp.11 - 18
김혜성 (차의과학대학교 임상약학대학원) , 정효근 (보훈공단 중앙보훈병원 약제실) , 심미경 (차의과학대학교 임상약학대학원)
Background: Nivolumab and pembrolizumab are antagonists of the programmed death-ligand 1 (PD-L1) receptor that function as immuno-oncological agents. This study aimed to evaluate the safety and efficacy of nivolumab and pembrolizumab in elderly patients in outpatient settings. Methods: The safety an...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Siegel, Rebecca L., Miller, Kimberly D., Jemal, Ahmedin. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, vol.68, no.1, 7-30.
Jung, Kyu-Won, Won, Young-Joo, Kong, Hyun-Joo, Lee, Eun Sook. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016. Cancer research and treatment : official journal of Korean Cancer Association, vol.51, no.2, 417-430.
Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., Massard, C., Fuerea, A., Ribrag, V., Gazzah, A., Armand, J.P., Amellal, N., Angevin, E., Noel, N., Boutros, C., Mateus, C., Robert, C., Soria, J.C., Marabelle, A., Lambotte, O.. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European journal of cancer, vol.54, 139-148.
Kang, Yoon-Koo, Boku, Narikazu, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Chen, Li-Tzong. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, vol.390, no.10111, 2461-2471.
Herbst, Roy S, Baas, Paul, Kim, Dong-Wan, Felip, Enriqueta, Pérez-Gracia, José L, Han, Ji-Youn, Molina, Julian, Kim, Joo-Hang, Arvis, Catherine Dubos, Ahn, Myung-Ju, Majem, Margarita, Fidler, Mary J, de Castro Jr, Gilberto, Garrido Jr, Marcelo, Lubiniecki Jr, Gregory M, Shentu Jr, Yue, Im Jr, Ellie, Dolled-Filhart Jr, Marisa, Garon Jr, Edward B. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, vol.387, no.10027, 1540-1550.
Montecino-Rodriguez, Encarnacion, Berent-Maoz, Beata, Dorshkind, Kenneth. Causes, consequences, and reversal of immune system aging. The Journal of clinical investigation, vol.123, no.3, 958-965.
Hao, Chunyan, Tian, Jinhui, Liu, Huiling, Li, Fei, Niu, Hongxia, Zhu, Bingdong. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma : A systematic review and meta-analysis of randomized controlled trials. Medicine, vol.96, no.26, e7325-.
Johnson, Douglas B., Sullivan, Ryan J., Menzies, Alexander M.. Immune checkpoint inhibitors in challenging populations. Cancer, vol.123, no.11, 1904-1911.
Kanesvaran, Ravindran, Cordoba, Raul, Maggiore, Ronald. Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. American society of clinical oncology educational book, vol.38, 400-414.
Health insurance review & assessment service. Question and answer for medical care application of immune checkpoint inhibitors, nivolumab and pembrolizumab. Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030023080000&brdScnBltNo=4&brdBltNo=45624#none . Accessed August 25th, 2019.
Passiglia, Francesco, Galvano, Antonio, Rizzo, Sergio, Incorvaia, Lorena, Listì, Angela, Bazan, Viviana, Russo, Antonio. Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. International journal of cancer: Journal international du cancer, vol.142, no.6, 1277-1284.
Ellis, P.M., Vella, E.T., Ung, Y.C.. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. Clinical lung cancer, vol.18, no.5, 444-459.e1.
Tie, Yan, Ma, Xuelei, Zhu, Chenjing, Mao, Ye, Shen, Kai, Wei, Xiawei, Chen, Yan, Zheng, Heng. Safety and efficacy of nivolumab in the treatment of cancers: A meta‐analysis of 27 prospective clinical trials. International journal of cancer: Journal international du cancer, vol.140, no.4, 948-958.
Wang, Manni, Ma, Xuelei, Guo, Linghong, Xia, Fan. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug design, development and therapy, vol.11, 2851-2860.
Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G., Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O’Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leiby, Melanie A., Lubiniecki, Gregory M., Shentu, Yue, Rangwala, Reshma, Brahmer, Julie R.. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine, vol.375, no.19, 1823-1833.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.